Molecular Characterization of the Tumor Suppressor Candidate 5 Gene: Regulation by PPAR𝛾 and Identification of TUSC5 Coding Variants in Lean and Obese Humans

Figure 1

Dose-Response of Tusc5 Gene Expression to Short-term Treatment with PPAR𝛾 Agonists in Mature 3T3-L1 Adipocytes. (a) Relative Tusc5 mRNA abundance in response to increasing concentrations of the potent and highly-selective non-thiazolidinedione GW1929. (b) Relative Tusc5 mRNA abundance in response to increasing concentrations of the thiazolidinedione troglitazone. Also shown for both conditions is expression of the aP2 gene, used as a positive control PPAR𝛾 target gene. Symbols represent the mean ± SEM for 𝑛=4/agonist concentration.

(a)

(b)